Highlights BeiGene, Ltd.

Equities

BGNE

US07725L1026

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
153.1 ^USD	+0.26%		-8.53%	-15.11%

May. 28	BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study	MT
May. 28	BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study	May. 28	MT
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments	May. 28	MT
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study	May. 28	CI
BeiGene Says Studies Highlight Effectiveness, Safety of Lymphoma Drug Brukinsa	May. 24	MT
BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL	May. 24	CI
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India	May. 21	MT
Glenmark Specialty S.A. Announces an Exclusive Marketing and Distribution Agreement with BeiGene	May. 20	CI
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024	May. 14	CI
Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up	May. 08	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	May. 08	MT
BeiGene's Q1 Loss Narrows as Revenue Rises	May. 08	MT
Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $752M	May. 08	MT
BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
BeiGene, Ltd. Anticipates Opening of Biologics Manufacturing Facility and Clinical R&D Center at the Princeton West Innovation Campus in Hopewell, New Jersey, in July 2024	May. 08	CI
Amgen Posts Higher 1Q Revenue, Swings to Loss	May. 02	DJ
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	Apr. 23	MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer	Apr. 23	MT
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	Apr. 23	CI
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	Apr. 10	MT
Beigene Shrinks Loss by 56% in 2023	Mar. 29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BeiGene, Ltd.

Equities

BGNE

US07725L1026

Highlights

Filters